Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CAMBRIDGE, Mass., Aug. 02, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled with predictive biomarkers for patient enrichment, today announced that it will report second quarter 2017 financial results on Wednesday, August 9, 2017. Jounce Therapeutics' management team will host a conference call and live audio webcast to discuss these results and provide a corporate update at 8:00 a.m. ET.
Conference Call and Webcast
To access the conference call, please dial (833) 584-0037 (domestic) or (409) 350-3605 (international) and refer to conference ID 61078435. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s wesbite approximately two hours after the call and will be available for 30 days.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 2 trial. For more information, please visit www.jouncetx.com.
Media Contact: Katie Engleman Pure Communications, Inc. (919) 333-7722 [email protected] Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
